Purple Biotech Presents New Preclinical Data at EACR 2026 Highlighting IM1240's Anti-Tumor Activity, Favorable Safety and Pharmacokinetic Profile, and Broad Therapeutic Window
Go back to Purple Biotech Presents New Preclinical Data at EACR 2026 Highlighting IM1240's Anti-Tumor Activity, Favorable Safety and Pharmacokinetic Profile, and Broad Therapeutic Window| (NASDAQ: PPBT) | Delayed: 1.43 +0.04 (2.88%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.39 | 52 Week High | $ | |||
| Open | $1.36 | 52 Week Low | $ | |||
| Day High | $1.51 | P/E | N/A | |||
| Day Low | $1.36 | EPS | $ | |||
| Volume | 9,651 | |||||
| (NASDAQ: PPBT) | Delayed: 1.43 +0.04 (2.88%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.39 | 52 Week High | $ | |||
| Open | $1.36 | 52 Week Low | $ | |||
| Day High | $1.51 | P/E | N/A | |||
| Day Low | $1.36 | EPS | $ | |||
| Volume | 9,651 | |||||

